|
Daniel S. Lynch
President and CEO
Dan Lynch is the President, CEO and a Director of Ivrea
Pharmaceuticals. He also serves on the Board of Directors and
the Audit Committee of U.S. Oncology, Inc.
Previously, Dan served as CFO and then CEO and a Director of
ImClone Systems Inc. Prior to ImClone, he held the position of
Chief Financial Officer of Derby Cycle Corporation. Dan also
served for 15 years in various financial capacities at
Bristol-Myers Squibb Company, including Vice President positions
for the U.S. Pharmaceuticals business, Worldwide Manufacturing
operations, International Pharmaceuticals business, and the
Worldwide Consumer Medicines business.
Dan received his Bachelor of Arts in Mathematics from
Wesleyan University and his M.B.A. from the Darden Graduate
School of Business Administration at The University of Virginia.
David Neafus
CFO
David Neafus has served as our CFO since March 2008. Over the previous twelve years, Dave operated his own consulting firm providing executive services, specializing in interim executive management, IPO’s, turnarounds, strategic analysis, and mergers and acquisitions. Previous clients include GlycoFi, where as CFO David helped the Company complete its $400 Million acquisition by Merck, Alnylam Pharmaceuticals, Inc. where as Vice President of Finance David led the company to a successful IPO, Infinity Pharmaceuticals where David served as Vice President Finance and Administration and Millennium Pharmaceuticals where he served as Corporate Controller.
Prior to running his own consulting firm, David was an auditor at KPMG. Mr. Neafus received his bachelor’s degree in accounting from the University of Minnesota, and his MBA from Bentley College.
He is also a certified public accountant.
|
